Kiniksa Pharmaceuticals Ltd. (KNSA) shares surged 7.77% in pre-market trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year revenue guidance.
The biopharmaceutical company reported Q2 earnings per share (EPS) of $0.23, surpassing the analyst estimate of $0.18. Kiniksa's Q2 sales reached $156.797 million, exceeding the expected $145.218 million. The company's net income for the quarter stood at $17.832 million, with a pretax profit of $22.877 million, showcasing robust financial performance.
In a significant move, Kiniksa raised its 2025 net product revenue guidance for ARCALYST, its flagship product. The company now expects ARCALYST to generate between $625 million and $640 million in revenue for the year, up from the previous guidance of $590 million to $605 million. This upward revision signals strong confidence in the drug's market performance and potential growth. Additionally, Kiniksa announced the initiation of a Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis, with Phase 2 data expected in the second half of 2026, further bolstering its pipeline prospects.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。